BioMarin Pharmaceutical (BMRN) Earnings Date, Estimates & Call Transcripts $65.66 +0.66 (+1.02%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BioMarin Pharmaceutical Latest Earnings SummaryActual EPS (Oct. 29) $0.55 Missed By -$0.23 Consensus EPS (Oct. 29) $0.78 BioMarin Pharmaceutical announced Q3 2024 earnings on October 29, 2024, reporting an EPS of $0.55, which missed the consensus estimate of $0.78 by $0.23. Quarterly revenue rose 28.4% year-over-year to $746 million, above analysts' expectations of $703.37 million. With a trailing EPS of $1.67 and a P/E Ratio of 39.32, BioMarin Pharmaceutical's earnings are expected to grow 21.29% next year, from $2.49 to $3.02 per share. Conference CallConference Call TranscriptEarnings Press ReleaseEarnings Slide DeckSEC 10-Q/10-K FilingPowered by Get BioMarin Pharmaceutical Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioMarin Pharmaceutical and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBMRN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BMRN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. BioMarin Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20242$0.36$0.36$0.36 Q2 20242$0.36$0.61$0.49 Q3 20243$0.53$0.71$0.65 Q4 20243$0.49$0.63$0.57 FY 202410$1.74$2.31$2.06 Q1 20253$0.48$0.68$0.59 Q2 20253$0.68$0.81$0.74 Q3 20253$0.72$0.83$0.79 Q4 20253$0.66$0.82$0.72 FY 202512$2.54$3.14$2.83 Q1 20261$0.76$0.76$0.76 Q2 20261$0.83$0.83$0.83 Q3 20261$0.86$0.86$0.86 BioMarin Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails10/29/2024Q3 2024$0.78$0.55 -$0.23$0.93$703.37M$746.00M8/5/2024Q2 2024$0.38$0.77+$0.39$0.99$660.51M$712.03M4/24/2024Q1 2024$0.37$0.49+$0.12$0.52$649.75M$648.83M2/22/2024Q4 2023$0.4450$0.49+$0.0450$0.41$639.53M$646.21M11/1/2023Q3 2023$0.28$0.26 -$0.02$0.31$603.51M$581.33M7/31/2023Q2 2023$0.24$0.34+$0.10$0.39$591.46M$595.28M Get the Latest News and Ratings for BMRN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 4/26/2023Q1 2023$0.24$0.39+$0.15$0.51$572.53M$596.42M2/27/2023Q4 2022$0.12$0.11 -$0.01$0.22$533.88M$537.54M BioMarin Pharmaceutical Earnings - Frequently Asked Questions When did BioMarin Pharmaceutical announce their last quarterly earnings? BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earning data on Tuesday, October 29, 2024. Learn more on BMRN's earnings history. What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical issued an update on its FY 2024 earnings guidance on Tuesday, September, 24th. The company provided earnings per share (EPS) guidance of 3.100-3.250 for the period, compared to the consensus earnings per share estimate of 2.040. The company issued revenue guidance of $2.8 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. Did BioMarin Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, BioMarin Pharmaceutical (NASDAQ:BMRN) missed the analysts' consensus estimate of $0.78 by $0.23 with a reported earnings per share (EPS) of $0.55. Learn more on analysts' earnings estimate vs. BMRN's actual earnings. How can I listen to BioMarin Pharmaceutical's earnings conference call? The conference call for BioMarin Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read BioMarin Pharmaceutical's conference call transcript? The conference call transcript for BioMarin Pharmaceutical's latest earnings report can be read online. Read Transcript How can I view BioMarin Pharmaceutical's earnings report? BioMarin Pharmaceutical's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded annual revenue of $2.75 billion. How much profit does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded net income of $167.65 million. BMRN has generated $1.67 earnings per share over the last four quarters. What is BioMarin Pharmaceutical's price-to-earnings ratio? BioMarin Pharmaceutical (NASDAQ:BMRN) has a trailing price-to-earnings ratio of 39.32 and a forward price-to-earnings ratio of 26.37. The price/earnings-to-growth ratio is 0.65. What is BioMarin Pharmaceutical's EPS forecast for next year? BioMarin Pharmaceutical's earnings are expected to grow from $2.49 per share to $3.02 per share in the next year, which is a 21.29% increase. More Earnings Resources from MarketBeat Related Companies ALNY Earnings Date BIIB Earnings Date UTHR Earnings Date NBIX Earnings Date INCY Earnings Date EXAS Earnings Date EXEL Earnings Date RGEN Earnings Date MDGL Earnings Date HALO Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. This page (NASDAQ:BMRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRN Stock Alerts